US Patent 7884181 Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
Patent 7884181 was granted and assigned to Novo Nordisk on February, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+110 characters)
Article
Patent abstract
The invention provides a pharmaceutical formulation and a method for preparing the formulation.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07884181 Pharmaceutical formulation comprising crystalline insulin and dissolved insulin US Patent 7884181 Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
Infobox
Patent Number
0788418100
Patent Number
788418100
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 28 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078841810
Date of Patent
February 8, 2011
0Patent Application Number
116644070
Date Filed
October 5, 2005
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078841810
Date of Patent
February 8, 2011
0Patent Application Number
116644070
Date Filed
October 5, 2005
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07884181 Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07884181
Date of patent
February 8, 2011
Patent application number
11664407
Date Filed
October 5, 2005
Patent primary examiner
Find more entities like US Patent 7884181 Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
